When including all studied samples of HGD and adenocarcinoma, and detected Barrett’s metaplasia samples in LGD groups, aberrant (either loss of expression or overexpression) p53 expression increased during follow-up in patients with progressive disease when compared to non-progressive patients (Fig. 3). This evidence concerns the gene TP53 and Barrett esophagus.